EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Select your location
Local sites
The future state of transfer pricing controversy for life sciences
In this webcast, we are going to explore the impact of tax legislative developments, technical positions and audit techniques on life sciences companies.
EY’s global team of transfer pricing leaders will discuss how these emerging controversy trends are likely to impact future transfer pricing policy and planning, as well as proactive measures life sciences companies can take now to mitigate future controversy risk.
The session will also explore how Pillar One Amount B may affect distribution returns, country positions on control over risk and the Economic Substance Doctrine.
Topics discussed include:
- The evolving transfer pricing controversy environment in the US, Europe and Canada
- Implications for operating model design and IP planning strategies
- Recommendations for steps life sciences companies can be taking today to navigate a rapidly intensifying global transfer pricing controversy environment more effectively
Moderator:
- Ana Maria Romero, EY US Life Sciences Transfer Pricing and IP Leader
Participants:
- Tracee Fultz, EY Global Transfer Pricing Leader
- Kent Stackhouse, EY US Transfer Pricing National Tax Leader
- Tara Di Rosa, EY Canada Transfer Pricing Canadian Market Leader
- Oliver Wehnert, EY EMEA Life Sciences Tax Leader